2013
DOI: 10.1590/s0074-02762013000100016
|View full text |Cite
|
Sign up to set email alerts
|

Cross-reactive anti-PfCLAG9 antibodies in the sera of asymptomatic parasite carriers of Plasmodium vivax

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 47 publications
0
11
0
Order By: Relevance
“…However, the presence of submicroscopic infections or the presence of residual antibodies from a previous infection(s) could not be ruled out by those authors. Similarly, there is a strong indication of the presence of cross-reactive responses to other sexual (17) and asexual (3,16,18) blood-stage antigens from the field. However, the data cannot be exclusively attributed to cross-reaction, as the presence of heterologous species, while rare, has not been ruled out.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, the presence of submicroscopic infections or the presence of residual antibodies from a previous infection(s) could not be ruled out by those authors. Similarly, there is a strong indication of the presence of cross-reactive responses to other sexual (17) and asexual (3,16,18) blood-stage antigens from the field. However, the data cannot be exclusively attributed to cross-reaction, as the presence of heterologous species, while rare, has not been ruled out.…”
Section: Resultsmentioning
confidence: 99%
“…Despite the presence of orthologous antigens, few studies have evaluated the presence of cross-reactive antibodies. Sera from regions with a predominance of one species, but not a total absence of the other species, have been shown to have cross-reactivity to some antigens, such as merozoite surface protein 1 (MSP-1) (15), MSP-5 (16), P. falciparum s48/45 (Pfs48/45) or P. vivax s48/45 (Pvs48/45) (17), and PfCLAG9 (18). Using P. falciparum and P. vivax protein microarrays, King and colleagues (3) observed cross-reactivity using sera from "essentially monoexposed" regions of endemicity.…”
mentioning
confidence: 99%
“…This suggests that some Pf and Pv orthologs may share linear or conformational epitopes that elicit cross-reactive antibodies able to protect against symptomatic Pf, Pv, or Pf/Pv infections. Naturally-acquired crossreactive antibody responses to MSP5 (75) and CLAG9 (76) have been observed in other endemic settings. Alternatively, it is possible that these apparent cross-reactive responses do not stem from shared epitopes between P. vivax and P. falciparum orthologous proteins, but instead could result from previous infections with the other Plasmodium species.…”
Section: S)mentioning
confidence: 85%
“…However, some studies have reported on cross-reactivity of few antigens specific to pre-erythrocytic and erythrocytic asexual stages of multiple Plasmodium species. This includes: (i) recognition of P. falciparum asexual stage antigens by antibodies in sera from people exposed to P. vivax , (Kumar et al, 1992), and suppression of P. falciparum by sera from a case of P. vivax (Nagao et al, 2008), (ii) recognition of circumsporozoite protein (CSP) of P. falciparum and P. berghei by antibodies elicited by VMP001, a P. vivax CSP-based vaccine (VMP00) (Yadava et al, 2012), (iii) induction of cross-reactive and cross-protective antibodies by PfCelTOS, a highly conserved cell-traversal protein expressed on the surface of ookinetes and sporozoites (Bergmann-Leitner et al, 2010), and (iv) reported cross reactivity between apical membrane antigen 1, cytoadherence-linked asexual gene 9 product and merozoite surface protein 5 of P. falciparum and P. vivax (Costa et al, 2013; Igonet et al, 2007; Woodberry et al, 2008). …”
Section: Introductionmentioning
confidence: 99%